HAE — Haemonetics Corporation

Haemonetics Corporation (HAE) Q4 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $346 million, up 5% reported and 9% organic (excluding CSL).
• Adjusted EPS: $1.29, a 4% increase year-over-year.
• Full Year Revenue: $1.3 billion, with adjusted EPS of $4.96, reflecting improved margins and cash flow despite $153 million in nonrecurring revenue from portfolio transitions.
• Adjusted Gross Margin: 59.7% in Q4, down 50 basis points year-over-year; full year adjusted gross margin expanded to 60.3%.
• Free Cash Flow: $45 million in Q4, totaling $210 million for the year, with a conversion ratio of 89%.

2. Strategic Updates and Business Highlights

• Core Platforms: Strong performance in blood management technologies, with a record quarter showing 21% growth, driven by TEG 6s and transfusion management.
• Interventional Technologies: Revenue declined 10% in Q4, but improvements expected with label expansions and new product launches, including MVP XL and PerQseal Elite.
• Innovation: FDA clearance of Persona PLUS and expanded indications for VASCADE MVP XL, alongside the acquisition of Vivasure, are key strategic moves.
• Plasma Business: Revenue of $130 million in Q4, up 3% reported and 13% organic (ex-CSL), with strong market fundamentals supporting growth.

3. Forward Guidance and Outlook

• Fiscal Year 2027 Guidance: Projected revenue growth of 4% to 7% reported and 3% to 6% organic, with adjusted EPS growth expected to align with revenue growth.
• Operational Improvements: Anticipated margin expansion of 50 to 100 basis points year-over-year, driven by gross margin improvements and operating leverage.
• Plasma Growth: Mid-single-digit growth outlook, with potential upside from collection trends and Persona PLUS adoption.

4. Bad News, Challenges, or Points of Concern

• Interventional Technologies Decline: Revenue down 10% in Q4, with ongoing challenges in vascular closure and market dynamics affecting performance.
• Tariff Impacts: Higher-than-expected tariffs and increased costs from self-insured medical plans impacted margins.
• Portfolio Rationalization: Ongoing adjustments and divestitures may continue to pose near-term headwinds, particularly in the blood center segment.
• Market Competition: Concerns regarding pricing pressures and competition in the plasma market, particularly related to FcRn therapies.

5. Notable Q&A Insights

• Plasma Collection Trends: Management noted a return to double-digit growth in collection volume towards the end of FY '26, but guidance for FY '27 includes conservative estimates of 0% to 2% growth.
• Persona PLUS Rollout: Strong customer interest and potential for pricing benefits from the new system, which is expected to enhance yield significantly.
• IVT Business Outlook: Management expressed renewed confidence in IVT growth, citing improved market dynamics and the potential for a turnaround in performance.
• Vivasure Acquisition: Early signals of interest in the Vivasure platform are positive, with a total addressable market estimated at $300 million, although no revenue is included in FY '27 guidance as the product is still under FDA review.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Haemonetics' performance and outlook.